{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:54:43Z","timestamp":1789588483969,"version":"build-2803163510"},"reference-count":82,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T00:00:00Z","timestamp":1698192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Rho kinase (ROCK) inhibitors have gained significant attention as emerging novel treatment options in the field of ophthalmology in recent years. The evidence supporting their efficacy in glaucoma and corneal pathology includes both in vitro and clinical studies. Among the available options, ripasudil and netarsudil have emerged as the leading ROCK inhibitors, and some countries have approved these therapeutic options as treatments for glaucoma. Various dosing regimens have been studied, including monotherapy and combination therapy, especially for patients with secondary glaucoma who are already on multiple medications. Another rising application of ROCK inhibitors includes their use as an adjunct in surgical procedures such as Descemetorhexis Without Endothelial Keratoplasty (DWEK), Descemet Stripping Only (DSO) to accelerate visual recovery, glaucoma surgeries to reduce scarring process and allow better intraocular pressure (IOP) control, or after complicated anterior segment surgery to treat corneal oedema. This article provides a comprehensive overview of the existing literature in the field, offering recommendations for prescribing ROCK inhibitors and also discussing patient selection, drug efficacy, and possible adverse effects.<\/jats:p>","DOI":"10.3390\/jcm12216736","type":"journal-article","created":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T06:19:58Z","timestamp":1698214798000},"page":"6736","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["ROCK Inhibitors in Corneal Diseases and Glaucoma\u2014A Comprehensive Review of These Emerging Drugs"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8534-6817","authenticated-orcid":false,"given":"Luca","family":"Pagano","sequence":"first","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University, 20072 Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason William","family":"Lee","sequence":"additional","affiliation":[{"name":"Clinical Eye Research Centre, St Paul\u2019s Eye Unit, Royal Liverpool University Hospital, Liverpool L7 8YE, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3983-0381","authenticated-orcid":false,"given":"Matteo","family":"Posarelli","sequence":"additional","affiliation":[{"name":"Department of Corneal Diseases, St. Paul\u2019s Eye Unit, Royal Liverpool University Hospital, Liverpool L7 8YE, UK"},{"name":"Ophthalmology Unit of the Department of Medicine, Surgery and Neuroscience, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2617-0289","authenticated-orcid":false,"given":"Giuseppe","family":"Giannaccare","sequence":"additional","affiliation":[{"name":"Eye Clinic, Department of Surgical Sciences, University of Cagliari, 09124 Cagliari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Kaye","sequence":"additional","affiliation":[{"name":"Department of Corneal Diseases, St. Paul\u2019s Eye Unit, Royal Liverpool University Hospital, Liverpool L7 8YE, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Borgia","sequence":"additional","affiliation":[{"name":"Department of Corneal Diseases, St. Paul\u2019s Eye Unit, Royal Liverpool University Hospital, Liverpool L7 8YE, UK"},{"name":"Eye Unit, Humanitas-Gradenigo Hospital, 10122 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,10,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"44","DOI":"10.5005\/jp-journals-10078-1396","article-title":"Rho-kinase Inhibitors in Ocular Diseases: A Translational Research Journey","volume":"17","author":"Singh","year":"2023","journal-title":"J. Curr. Glaucoma Pract."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/IJG.0000000000001730","article-title":"Economic and Clinical Burden Associated With Intensification of Glaucoma Topical Therapy: A US Claims-based Analysis","volume":"30","author":"Patel","year":"2021","journal-title":"J. Glaucoma"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1161\/01.RES.0000196564.18314.23","article-title":"Rho GTPases, statins, and nitric oxide","volume":"97","author":"Rikitake","year":"2005","journal-title":"Circ. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1167\/iovs.12-11320","article-title":"The ROCK inhibitor eye drop accelerates corneal endothelium wound healing","volume":"54","author":"Okumura","year":"2013","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Peh, G.S.L., Bandeira, F., Neo, D., Adnan, K., Hartono, Y., Ong, H.S., Naso, S., Venkatraman, A., Gomes, J.A.P., and Kocaba, V. (2023). Effects of Rho-Associated Kinase (Rock) Inhibitors (Alternative to Y-27632) on Primary Human Corneal Endothelial Cells. Cells, 12.","DOI":"10.3390\/cells12091307"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1167\/iovs.13-12225","article-title":"Involvement of cyclin D and p27 in cell proliferation mediated by ROCK inhibitors Y-27632 and Y-39983 during corneal endothelium wound healing","volume":"55","author":"Okumura","year":"2014","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1097\/ICO.0000000000002855","article-title":"Descemetorhexis Without Endothelial Keratoplasty in Fuchs Endothelial Corneal Dystrophy: A Systematic Review and Meta-Analysis","volume":"41","author":"Franceschino","year":"2022","journal-title":"Cornea"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1167\/iovs.10-5265","article-title":"Effects of fasudil, a Rho-associated protein kinase inhibitor, on optic nerve head blood flow in rabbits","volume":"52","author":"Sugiyama","year":"2011","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ajo.2022.11.017","article-title":"Ripasudil-Brimonidine Fixed-Dose Combination vs. Ripasudil or Brimonidine: Two Phase 3 Randomized Clinical Trials","volume":"248","author":"Tanihara","year":"2023","journal-title":"Am. J. Ophthalmol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e393","DOI":"10.1111\/aos.12641","article-title":"Efficacy and safety of SNJ-1656 in primary open-angle glaucoma or ocular hypertension","volume":"93","author":"Inoue","year":"2015","journal-title":"Acta Ophthalmol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.exer.2016.08.023","article-title":"Role of the Rho GTPase\/Rho kinase signaling pathway in pathogenesis and treatment of glaucoma: Bench to bedside research","volume":"158","author":"Rao","year":"2017","journal-title":"Exp. Eye Res."},{"key":"ref_12","first-page":"101","article-title":"Use of Rho kinase Inhibitors in Ophthalmology: A Review of the Literature","volume":"7","author":"Moshirfar","year":"2018","journal-title":"Med. Hypothesis Discov. Innov. Ophthalmol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s00417-019-04283-5","article-title":"Rho kinase inhibitors-a review on the physiology and clinical use in Ophthalmology","volume":"257","author":"Bruxelas","year":"2019","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1167\/iovs.09-4391","article-title":"Divergent roles of nitric oxide and rho kinase in vasomotor regulation of human retinal arterioles","volume":"51","author":"Hein","year":"2010","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00417-018-4191-6","article-title":"Effects of ripasudil, a rho kinase inhibitor, on blood flow in the optic nerve head of normal rats","volume":"257","author":"Wada","year":"2019","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e22397","DOI":"10.1096\/fj.202101442RR","article-title":"Inhibition of Rho-associated protein kinase activity enhances oxidative phosphorylation to support corneal endothelial cell migration","volume":"36","author":"Ho","year":"2022","journal-title":"FASEB J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"175163","DOI":"10.1155\/2010\/175163","article-title":"ROCK as a Therapeutic Target of Diabetic Retinopathy","volume":"2010","author":"Arita","year":"2010","journal-title":"J. Ophthalmol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Mateos-Olivares, M., Garcia-Onrubia, L., Valentin-Bravo, F.J., Gonzalez-Sarmiento, R., Lopez-Galvez, M., Pastor, J.C., Usategui-Mart\u00edn, R., and Pastor-Idoate, S. (2021). Rho-Kinase Inhibitors for the Treatment of Refractory Diabetic Macular Oedema. Cells, 10.","DOI":"10.3390\/cells10071683"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1001\/jamaophthalmol.2013.323","article-title":"Phase 1 clinical trials of a selective Rho kinase inhibitor, K-115","volume":"131","author":"Tanihara","year":"2013","journal-title":"JAMA Ophthalmol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.ajo.2013.05.016","article-title":"Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension","volume":"156","author":"Tanihara","year":"2013","journal-title":"Am. J. Ophthalmol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1001\/jamaophthalmol.2015.0525","article-title":"Additive Intraocular Pressure-Lowering Effects of the Rho Kinase Inhibitor Ripasudil (K-115) Combined With Timolol or Latanoprost: A Report of 2 Randomized Clinical Trials","volume":"133","author":"Tanihara","year":"2015","journal-title":"JAMA Ophthalmol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1111\/aos.12829","article-title":"One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension","volume":"94","author":"Tanihara","year":"2016","journal-title":"Acta Ophthalmol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s12325-018-0863-1","article-title":"Safety and Efficacy of Ripasudil in Japanese Patients with Glaucoma or Ocular Hypertension: 3-month Interim Analysis of ROCK-J, a Post-Marketing Surveillance Study","volume":"36","author":"Tanihara","year":"2019","journal-title":"Adv. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s40261-017-0509-0","article-title":"Efficacy of Ripasudil as a Second-line Medication in Addition to a Prostaglandin Analog in Patients with Exfoliation Glaucoma: A Pilot Study","volume":"37","author":"Matsumura","year":"2017","journal-title":"Clin. Drug Investig."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s00417-018-3933-9","article-title":"Efficacy and safety of ripasudil, a Rho-associated kinase inhibitor, in eyes with uveitic glaucoma","volume":"256","author":"Kusuhara","year":"2018","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"10308","DOI":"10.1038\/s41598-020-66928-4","article-title":"Intraocular pressure-lowering effects of ripasudil in uveitic glaucoma, exfoliation glaucoma, and steroid-induced glaucoma patients: ROCK-S, a multicentre historical cohort study","volume":"10","author":"Futakuchi","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/IJG.0000000000000552","article-title":"Efficacy of the Additional Use of Ripasudil, a Rho-Kinase Inhibitor, in Patients With Glaucoma Inadequately Controlled Under Maximum Medical Therapy","volume":"26","author":"Inazaki","year":"2017","journal-title":"J. Glaucoma"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1007\/s12325-021-01775-x","article-title":"The Additive Effect of ROCK Inhibitor on Prostaglandin-Treated Japanese Patients with Glaucoma Indicating 15 mmHg and Under: ROCK U-15","volume":"38","author":"Sakata","year":"2021","journal-title":"Adv Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.4103\/ijo.IJO_3145_21","article-title":"Safety, efficacy, and patient selection of ripasudil in patients with uncontrolled glaucoma with maximum conventional medical therapy","volume":"70","author":"Jethva","year":"2022","journal-title":"Indian J. Ophthalmol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Mimura, T., Noma, H., Inoue, Y., Kawashima, M., Kitsu, K., and Mizota, A. (2022). Early Postoperative Effect of Ripasudil Hydrochloride After Trabeculectomy on Secondary Glaucoma: A Randomized Controlled Trial. Open Ophthalmol. J., 16.","DOI":"10.2174\/18743641-v16-e2206201"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"101160","DOI":"10.1016\/j.conctc.2023.101160","article-title":"A multicenter phase II study on the safety of rho-kinase inhibitor (ripasudil) with needling for the patients after trabeculectomy","volume":"33","author":"Mizuno","year":"2023","journal-title":"Contemp. Clin. Trials Commun."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/ICO.0000000000001209","article-title":"Descemetorhexis Without Grafting for Fuchs Endothelial Dystrophy-Supplementation With Topical Ripasudil","volume":"36","author":"Moloney","year":"2017","journal-title":"Cornea"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1097\/ICO.0000000000001742","article-title":"Descemetorhexis Without Endothelial Keratoplasty Versus DMEK for Treatment of Fuchs Endothelial Corneal Dystrophy","volume":"37","author":"Huang","year":"2018","journal-title":"Cornea"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1097\/ICO.0000000000002975","article-title":"Surgical Management of Fuchs Endothelial Corneal Dystrophy: A Treatment Algorithm and Individual Patient Meta-Analysis of Descemet Stripping Only","volume":"41","author":"Din","year":"2022","journal-title":"Cornea"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/ICO.0000000000002437","article-title":"Descemet Stripping Only Supplemented With Topical Ripasudil for Fuchs Endothelial Dystrophy 12-Month Outcomes of the Sydney Eye Hospital Study","volume":"40","author":"Moloney","year":"2021","journal-title":"Cornea"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/ICO.0000000000001883","article-title":"Use of Topical Rho Kinase Inhibitors in the Treatment of Fuchs Dystrophy After Descemet Stripping Only","volume":"38","author":"Macsai","year":"2019","journal-title":"Cornea"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2217\/rme-2021-0149","article-title":"Alternatives to endokeratoplasty: An attempt towards reducing global demand of human donor corneas","volume":"17","author":"Parekh","year":"2022","journal-title":"Regen. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1167\/tvst.10.4.18","article-title":"The ROCK Inhibitor Ripasudil Shows an Endothelial Protective Effect in Patients With Low Corneal Endothelial Cell Density After Cataract Surgery","volume":"10","author":"Fujimoto","year":"2021","journal-title":"Transl. Vis. Sci. Technol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e00075","DOI":"10.1097\/j.jcro.0000000000000075","article-title":"Corneal endothelial wound healing after Descemet tear with a rho kinase inhibitor","volume":"10","author":"Azhari","year":"2022","journal-title":"J. Cataract. Refract. Surg. Online Case Rep."},{"key":"ref_40","first-page":"NP13-8","article-title":"Descemet stripping only and ripasudil for the treatment of traumatic Descemet\u2019s membrane ruptures","volume":"33","author":"Chan","year":"2023","journal-title":"Eur. J. Ophthalmol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1097\/ICO.0000000000003282","article-title":"Topical Ripasudil for the Treatment of Segmental Corneal Edema: A Case Series","volume":"42","author":"Tseng","year":"2023","journal-title":"Cornea"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1016\/j.jcjo.2021.11.009","article-title":"Use of ripasudil for rapid resolution of acute hydrops in keratoconus","volume":"57","author":"Eslami","year":"2022","journal-title":"Can. J. Ophthalmol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1038\/s41598-019-40255-9","article-title":"Evaluation of offset of conjunctival hyperemia induced by a Rho-kinase inhibitor; 0.4% Ripasudil ophthalmic solution clinical trial","volume":"9","author":"Sakamoto","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/IJG.0000000000001203","article-title":"Long-term Side Effects Including Blepharitis Leading to Discontinuation of Ripasudil","volume":"28","author":"Saito","year":"2019","journal-title":"J. Glaucoma"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e251074","DOI":"10.1136\/bcr-2022-251074","article-title":"Honeycomb epithelial oedema due to ripasudil: Clinical, optical coherence tomography and histopathological correlation","volume":"15","author":"Jain","year":"2022","journal-title":"BMJ Case Rep."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.4103\/ijo.IJO_2865_21","article-title":"Reticular epithelial corneal edema as a novel side-effect of Rho Kinase Inhibitors: An Indian scenario","volume":"70","author":"Bhargava","year":"2022","journal-title":"Indian. J. Ophthalmol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Tanihara, H., Kakuda, T., Sano, T., Kanno, T., and Gunji, R. (2020). Safety and efficacy of ripasudil in Japanese patients with glaucoma or ocular hypertension: 12-month interim analysis of ROCK-J, a post-marketing surveillance study. BMC Ophthalmol., 20.","DOI":"10.1186\/s12886-020-01490-1"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1007\/s12325-021-02023-y","article-title":"Long-Term Intraocular Pressure-Lowering Effects and Adverse Events of Ripasudil in Patients with Glaucoma or Ocular Hypertension over 24 Months","volume":"39","author":"Tanihara","year":"2022","journal-title":"Adv. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Giles, A., Foushee, J., Lantz, E., and Gumina, G. (2019). Sulfonamide Allergies. Pharmacy, 7.","DOI":"10.3390\/pharmacy7030132"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ajo.2021.01.019","article-title":"Netarsudil Improves Trabecular Outflow Facility in Patients with Primary Open Angle Glaucoma or Ocular Hypertension: A Phase 2 Study","volume":"226","author":"Sit","year":"2021","journal-title":"Am. J. Ophthalmol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ophtha.2014.08.022","article-title":"Double-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure","volume":"122","author":"Bacharach","year":"2015","journal-title":"Ophthalmology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ajo.2019.06.016","article-title":"Netarsudil\/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure: Three-Month Data from a Randomized Phase 3 Trial","volume":"207","author":"Asrani","year":"2019","journal-title":"Am. J. Ophthalmol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ogla.2019.03.007","article-title":"Once-Daily Netarsudil\/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure in the Randomized Phase 3 MERCURY-2 Study","volume":"2","author":"Walters","year":"2019","journal-title":"Ophthalmol. Glaucoma"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Stalmans, I., Lim, K.S., Oddone, F., Fichtl, M., Belda, J.I., Hommer, A., Laganovska, G., Schweitzer, C., Voykov, B., and Zarnowski, T. (2023). MERCURY-3: A randomized comparison of netarsudil\/latanoprost and bimatoprost\/timolol in open-angle glaucoma and ocular hypertension. Graefes Arch. Clin. Exp. Ophthalmol.","DOI":"10.1007\/s00417-023-06192-0"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1097\/IJG.0000000000001634","article-title":"Pooled Efficacy and Safety Profile of Netarsudil Ophthalmic Solution 0.02% in Patients With Open-angle Glaucoma or Ocular Hypertension","volume":"29","author":"Singh","year":"2020","journal-title":"J. Glaucoma"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ajo.2017.11.019","article-title":"Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2)","volume":"186","author":"Serle","year":"2018","journal-title":"Am. J. Ophthalmol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ajo.2019.03.002","article-title":"Once-Daily Netarsudil Versus Twice-Daily Timolol in Patients With Elevated Intraocular Pressure: The Randomized Phase 3 ROCKET-4 Study","volume":"204","author":"Khouri","year":"2019","journal-title":"Am. J. Ophthalmol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.4103\/IJO.IJO_25_23","article-title":"Netarsudil monotherapy as the initial treatment for open-angle glaucoma and ocular hypertension in Indian patients: A real-world evaluation of efficacy and safety","volume":"71","author":"Mathur","year":"2023","journal-title":"Indian J. Ophthalmol."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Oydanich, M., Roll, E.H., Uppuluri, S., and Khouri, A.S. (2023). Effectiveness of netarsudil 0.02% in lowering intraocular pressure in patients with secondary glaucoma. Can. J. Ophthalmol.","DOI":"10.1016\/j.jcjo.2023.05.009"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1177\/11206721231159694","article-title":"Topical netarsudil for treatment of glaucoma with elevated episcleral venous pressure: A pilot investigation in sturge-weber syndrome","volume":"33","author":"Kaufman","year":"2023","journal-title":"Eur. J. Ophthalmol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/1120672121998913","article-title":"Experience with netarsudil 0.02% and latanoprostene bunod 0.024% as adjunctive therapy for glaucoma","volume":"32","author":"Mehta","year":"2022","journal-title":"Eur. J. Ophthalmol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.1007\/s12325-023-02550-w","article-title":"Phase 3 Clinical Trial Comparing the Safety and Efficacy of Netarsudil to Ripasudil in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: Japan Rho Kinase Elevated Intraocular Pressure Treatment Trial (J-ROCKET)","volume":"40","author":"Araie","year":"2023","journal-title":"Adv. Ther."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1007\/s00417-022-05609-6","article-title":"Response to netarsudil in goniotomy-treated eyes and goniotomy-naive eyes: A pilot study","volume":"260","author":"Xu","year":"2022","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ajo.2021.03.006","article-title":"Randomized, Double-Masked, Pilot Study of Netarsudil 0.02% Ophthalmic Solution for Treatment of Corneal Edema in Fuchs Dystrophy","volume":"227","author":"Price","year":"2021","journal-title":"Am. J. Ophthalmol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1089\/jop.2022.0069","article-title":"Phase 2, Randomized, Open-Label Parallel-Group Study of Two Dosing Regimens of Netarsudil for the Treatment of Corneal Edema Due to Fuchs Corneal Dystrophy","volume":"38","author":"Lindstrom","year":"2022","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_66","first-page":"6139026","article-title":"A Case Report Illustrating the Postoperative Course of Descemetorhexis without Endothelial Keratoplasty with Topical Netarsudil Therapy","volume":"2019","author":"Ploysangam","year":"2019","journal-title":"Case Rep. Ophthalmol. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/ICO.0000000000002195","article-title":"Descemet Stripping Only for a Chronic Descemet Detachment After Cataract Surgery","volume":"39","author":"Hirabayashi","year":"2020","journal-title":"Cornea"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"101087","DOI":"10.1016\/j.ajoc.2021.101087","article-title":"Case report: The use of netarsudil to improve corneal edema after laser peripheral iridotomy and Descemet\u2019s membrane endothelial keratoplasty","volume":"22","author":"Chen","year":"2021","journal-title":"Am. J. Ophthalmol. Case Rep."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1007\/s12325-020-01277-2","article-title":"Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy\/Safety Analysis of Phase 3 MERCURY-1 and -2","volume":"37","author":"Asrani","year":"2020","journal-title":"Adv. Ther."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/ICO.0000000000002694","article-title":"Honeycomb Epithelial Edema Associated with Rho Kinase Inhibition: A Case Series and Review of the Literature","volume":"41","author":"Lyons","year":"2022","journal-title":"Cornea"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"34","DOI":"10.5693\/djo.02.2022.02.002","article-title":"Reticular epithelial edema after penetrating keratoplasty in a patient taking netarsudil","volume":"28","author":"Jeang","year":"2022","journal-title":"Digit. J. Ophthalmol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"94","DOI":"10.4103\/ojo.ojo_2_22","article-title":"Reticular corneal epithelial edema with topical netarsudil","volume":"16","author":"Parmar","year":"2023","journal-title":"Oman J. Ophthalmol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"101638","DOI":"10.1016\/j.ajoc.2022.101638","article-title":"Two pediatric cases of reticular corneal epithelial edema associated with netarsudil","volume":"27","author":"Liebman","year":"2022","journal-title":"Am. J. Ophthalmol. Case Rep."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1159\/000524362","article-title":"Netarsudil-Induced Corneal Flattening in a Child with Secondary Open-Angle Glaucoma","volume":"13","author":"Ganesh","year":"2022","journal-title":"Case Rep. Ophthalmol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2013.05.002","article-title":"Rho-associated kinase inhibitors: A novel glaucoma therapy","volume":"37","author":"Inoue","year":"2013","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2646904","DOI":"10.1155\/2017\/2646904","article-title":"Application of Rho Kinase Inhibitors for the Treatment of Corneal Endothelial Diseases","volume":"2017","author":"Okumura","year":"2017","journal-title":"J. Ophthalmol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"5549","DOI":"10.1167\/iovs.07-0878","article-title":"Potential role of Rho-associated protein kinase inhibitor Y-27632 in glaucoma filtration surgery","volume":"48","author":"Honjo","year":"2007","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1167\/iovs.06-1271","article-title":"The Rho-kinase inhibitor H-1152P suppresses the wound-healing activities of human Tenon\u2019s capsule fibroblasts in vitro","volume":"48","author":"Tura","year":"2007","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/bs.pbr.2015.04.014","article-title":"Rho kinase inhibitor AMA0526 improves surgical outcome in a rabbit model of glaucoma filtration surgery","volume":"220","author":"Vandewalle","year":"2015","journal-title":"Prog. Brain Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1124\/jpet.106.110635","article-title":"Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities","volume":"320","author":"Doe","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1002\/art.23986","article-title":"Antiinflammatory effect of Rho kinase blockade via inhibition of NF-kappaB activation in rheumatoid arthritis","volume":"58","author":"He","year":"2008","journal-title":"Arthritis Rheum."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/S0016-5085(03)00283-X","article-title":"Rho kinase blockade prevents inflammation via nuclear factor kappa B inhibition: Evidence in Crohn\u2019s disease and experimental colitis","volume":"124","author":"Segain","year":"2003","journal-title":"Gastroenterology"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/21\/6736\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:11:24Z","timestamp":1760130684000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/21\/6736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,25]]},"references-count":82,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["jcm12216736"],"URL":"https:\/\/doi.org\/10.3390\/jcm12216736","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,25]]}}}